Scripps Research Launches Fully Remote Clinical Trial for Long COVID Treatment Using Repurposed Drug
核心洞察
Scripps Research (搜索) has initiated the Long Covid (搜索) Treatment Trial (LoCITT), a fully remote clinical study that will enroll 1,000 participants nationwide to evaluate a repurposed drug for Long COVID treatment.
The innovative trial design includes mailing medications, placebos, and wearable devices directly to patients' homes, enabling participation without requiring visits to clinical sites.
The remote approach specifically aims to include housebound and bed-bound patients, who represent about a quarter of Long COVID (搜索) patients and are systematically excluded from traditional trials.
Scripps Research (搜索) has launched the Long Covid (搜索) Treatment Trial (LoCITT), a groundbreaking fully remote clinical study that will evaluate a repurposed drug for treating Long COVID across the United States. The trial, supported by the Schmidt Initiative for Long Covid (搜索) (SILC) and conducted through CareEvolution (搜索)'s MyDataHelps platform, represents a significant shift toward accessible clinical research for post-viral syndromes.
Revolutionary Remote Trial Design
The LoCITT study plans to enroll 1,000 participants nationwide, with all trial activities—including enrollment, randomization, and data collection—completed remotely from patients' homes. Study medications or placebos will be mailed directly to participants, who will also receive wearable devices to monitor heart rate, sleep, and activity patterns.
"We have intentionally designed a remote trial to ensure we can include housebound and bed bound participants – which includes about a quarter of people with Long COVID (搜索) who are systematically excluded from trials that require participants to go to a specific location," explained Julia Moore Vogel, PhD, co-principal investigator of LoCITT, in an interview with Contagion.
Addressing Critical Research Gaps
The trial design directly addresses significant barriers in Long COVID (搜索) research. Traditional clinical trials often exclude the most severely affected patients who cannot travel to research sites, creating a substantial gap in understanding treatment effectiveness for the full spectrum of Long COVID severity.
Vogel noted that the research team "selected the candidate that we think has the best chance of making a difference for people with Long COVID (搜索) based on the data available at the time and complementing existing trials." While the specific repurposed drug has not been disclosed, the selection was based on scientific criteria and existing data supporting its potential efficacy.
Innovative Data Collection Methods
The study will employ a well-validated survey as its primary endpoint, while simultaneously working to validate the use of wrist-worn wearable devices for future trial applications. Researchers will maintain frequent contact with participants to ensure proper medication adherence, monitor for side effects, and provide necessary support throughout the study period.
"We aim to validate the use of data from wrist-worn wearables for primary endpoint use in future trials," Vogel stated, highlighting the potential for this approach to establish new standards in remote clinical research.
Defining Success and Future Impact
The research team has established clear metrics for both operational and clinical success. Operationally, success will be measured by meeting enrollment, retention, and adherence goals. Clinically, the team aims to demonstrate "a meaningful reduction of Long COVID (搜索) symptoms with minimal adverse events."
Beyond immediate treatment outcomes, the trial seeks to contribute to best practices for conducting accessible, remote trials and advance standards for decentralized research in Long COVID (搜索) and other post-viral syndromes.
Long COVID Burden and Risk Factors
According to the CDC (搜索), Long COVID (搜索) is a chronic condition that can develop at least three months after a SARS-CoV-2 (搜索) infection, affecting both adults and children. The condition is associated with a wide range of symptoms that may persist, recur, or worsen over time, and in some cases may result in disability.
The CDC (搜索) identifies several groups at higher risk for developing Long COVID (搜索), including women, Hispanic and Latino individuals, older adults, those with underlying conditions, unvaccinated individuals, and patients who experienced severe COVID-19 (搜索) illness. Currently, there is no single diagnostic test for Long COVID, and healthcare providers must rely on clinical history, examination, and evaluation to guide management.
Research Foundation
The LoCITT trial builds on Vogel's previous research published in October 2024, which analyzed existing Long COVID (搜索) clinical trials and emphasized the need for more rigorous, accessible, and inclusive study designs. Her analysis urged prioritization of pharmaceutical interventions, remote participation options, and diverse patient representation—recommendations that directly align with the LoCITT trial's design principles.
Patients interested in participating can sign up to receive notifications about the trial through CareEvolution (搜索)'s platform, marking a new era in accessible clinical research for Long COVID (搜索) treatment.